Author: Shibeeb, Sapha; Ahmad, Muneera Naseer
Title: Thrombotic and Hypercoagulability Complications of COVID-19: An Update Cord-id: itzbx74c Document date: 2021_8_31
ID: itzbx74c
Snippet: The current COVID-19 pandemic emerged in December 2019, in China, affecting millions of people worldwide. COVID-19 is mainly a disease of the respiratory system, yet systematic complications have also been reported among SARS-CoV-2 infected patients. Thrombotic complications are one of the severe clinical outcomes of COVID-19, especially among critically ill patients, and are associated with poor prognosis. To date, many studies have concluded that COVID-19 increases the incidence of thrombotic
Document: The current COVID-19 pandemic emerged in December 2019, in China, affecting millions of people worldwide. COVID-19 is mainly a disease of the respiratory system, yet systematic complications have also been reported among SARS-CoV-2 infected patients. Thrombotic complications are one of the severe clinical outcomes of COVID-19, especially among critically ill patients, and are associated with poor prognosis. To date, many studies have concluded that COVID-19 increases the incidence of thrombotic events and coagulopathies; however, the exact mechanism behind such a disease outcome is not well known. Various pathophysiological mechanisms for thrombotic events in COVID-19 have been proposed, these include virus-induced endothelial cell damage, inflammation, and excess production of pro-inflammatory cytokines. As a result, most critically diseased COVID-19 patients are managed with prophylactic anticoagulant, yet some still develop thrombotic episodes. Therefore, better understanding of the mechanisms behind the thrombotic complications is needed to develop treatments that specifically target such pathways, which may aid in better disease management and improve the prognosis.
Search related documents:
Co phrase search for related documents- abnormal coagulation and activation platelet adhesion: 1
- abnormal coagulation and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5
- abnormal coagulation and acute kidney injury: 1, 2, 3
- abnormal coagulation and low molecular weight: 1, 2, 3, 4, 5, 6, 7
- abnormal coagulation and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7
- abo blood group and acute ards respiratory distress syndrome: 1, 2
- activate factor and acute ards respiratory distress syndrome: 1
- activate factor and acute kidney injury: 1
- activation coagulation cascade and acute ards respiratory distress syndrome: 1, 2, 3, 4
- activation coagulation cascade and low molecular weight: 1, 2, 3
- activation coagulation cascade and low molecular weight heparin: 1, 2, 3
- activation platelet adhesion and acute ards respiratory distress syndrome: 1
- acute ards respiratory distress syndrome and low extent: 1
- acute ards respiratory distress syndrome and low icu admission: 1
- acute ards respiratory distress syndrome and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- acute ards respiratory distress syndrome and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute ards respiratory distress syndrome lead and low molecular weight: 1
- acute ards respiratory distress syndrome lead and low molecular weight heparin: 1
- acute kidney injury and low icu admission: 1, 2
Co phrase search for related documents, hyperlinks ordered by date